- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Conbercept efficacious in short-term treatment of Diabetic Macular Edema with or without Diabetic Nephropathy
Diabetic macular edema (DME) is a common complication of diabetes, and when coupled with diabetic nephropathy (DN), it poses additional challenges to management. In a recent retrospective study, researchers aimed to evaluate the therapeutic effects of conbercept on DME patients with and without DN.
This study was published in the International Journal Of Ophthalmology by Zhu YZ and colleagues.
The study included 54 patients diagnosed with DME, categorized into two groups: those with DN (25 eyes) and those without DN (29 eyes). Various parameters, including fasting blood glucose, HbA1c, microalbumin/creatinine, serum creatinine, central macular thickness (CMT), best corrected visual acuity (BCVA), and retinal hyperreflective foci (HF), were assessed before and during treatment. Optical coherence tomography (OCT) was utilized to evaluate ellipsoidal zone (EZ) and external limiting membrane (ELM) integrity.
The key findings of the study were:
Significant differences were observed between the two groups in fasting blood glucose, HbA1c, serum creatinine, urinary microalbumin/creatinine, and estimated glomerular filtration rate (eGFR).
EZ and ELM continuity were worse in the DME+DN group.
BCVA was significantly better in the DME group compared to the DME+DN group throughout treatment. CMT and HF values were higher in the DME+DN group and decreased with treatment in both groups over time.
The mean number of injections at 6 months was higher in the DME+DN group compared to the DME group.
Conbercept demonstrated significant efficacy in the short-term treatment of DME, with or without DN. It improved BCVA, CMT, and reduced HF counts. However, treatment efficacy was better in DME patients without DN. These findings highlight the potential of conbercept in managing DME, particularly in patients without DN. Further research is warranted to validate these results and explore long-term outcomes.
Reference:
Zhu YZ, Dou ZZ, Wang WY, Ma QY, Yi WD, Yao NN, Liu YC, Gao XD, Zhang Q, Luo WJ. Intravitreal injection of conbercept for diabetic macular edema complicated with diabetic nephropathy
DOI:10.18240/ijo.2024.02.12
Dr Riya Dave has completed dentistry from Gujarat University in 2022. She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information. She has been actively involved in writing blogs related to health and wellness.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751